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Introduction
Mutations in TNFR1 cause the familial autosomal-domi-
nant autoinflammatory disorder TNF receptor-associated
periodic syndrome (TRAPS). Most TRAPS-associated
mutations in TNFR1 disrupt normal receptor function
and cause retention of the mutant protein in the ER.
Cells expressing mutant TNFR1 have enhanced MAP
Kinase activation at baseline and hyper-responsiveness to
innate immune stimuli, which is aided by the wild-type
receptor. We have previously found that reactive oxygen
species (ROS) generated by mitochondrial respiration is
critical for this phenotype [1]. TRAPS patient cells, and
cells from TNFR1 mutant mice display enhanced basal
and maximal oxygen consumption, suggesting that
enhanced mitochondrial respiration can in some circum-
stances contribute to acute inflammatory responses
through increased generation of ROS.
Objectives
To identify the metabolic and mitochondrial abnormalities
underlying increased ROS production and hyper-
inflammatory responses of TRAPS cells and more gener-
ally, the role of mitochondrial ROS in acute inflammatory
responses and production of pro-inflammatory cytokines.
Methods
Oxygen consumption, reactive oxygen species generation,
and cytokine production was measured in mouse embryo-
nic fibroblasts and macrophages from mice harboring
TRAPS-associated TNFR1 mutations and peripheral blood
monocytes from TRAPS patients. Agents that disrupt spe-
cific complexes in the electron transport chain (ETC) or
import of key substrates into mitochondria were used
to dissect the sources of increased ROS production,
mitochondrial oxygen consumption and transcription of
pro-inflammatory cytokines and chemokines after treat-
ment with innate immune activating stimuli such as LPS.
Results
Experiments with permeablized cells fed with ETC
substrates showed no intrinsic abnormalities in com-
plexes I-IV of the ETC. Fatty acid supplementation and
etomoxir, which blocks fatty acid uptake by mitochon-
dria, showed that fatty acid oxidation and delivery to
mitochondria is a key driver of increased spare respira-
tory capacity in TNFR1 mutant cells. However inflamma-
tory cytokine production in response to LPS is not
reduced in the presence of etomoxir in normal cells or
those harboring TNFR1 mutations. Rather, inhibition of
glycolysis was more effective in reducing macrophage
production of IL-6 and IL-1.
Conclusion
Enhanced inflammatory cytokine production in TRAPS
is a result of altered cellular metabolism rather than
intrinsic abnormalities in the mitochondrial ETC.
Increased mitochondrial fatty acid metabolism accounts
for the increased mitochondrial respiratory reserve, but
not inflammatory cytokine production in TNFR1 mutant
or normal macrophages. These results emphasize the
pathogenic role of mitochondrial ROS in inflammatory
responses, which is is being investigated using mito-
chondria-targeted antioxidants in mouse models and a
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